Rakovina Therapeutics expands Variational AI pact, gains exclusivity on kt-5000 ATR inhibitor target profile

• Rakovina Therapeutics amended, extended its research services deal with Variational AI for the kt-5000 ATR inhibitor program.
• Amendment grants exclusivity on a defined target product profile covering potency, selectivity, drug-like properties, brain penetration for the agreed term.
• Variational AI to run additional Enki lead-optimization cycles beyond five already delivered at no added cost to Rakovina.
• Variational AI to receive higher milestone payments tied to drug-candidate nomination, completion of an out-licensing transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140530PRIMZONEFULLFEED9845232) on October 14, 2026, and is solely responsible for the information contained therein.